CECIF ☆ Colombia, 2017-10-11 20:18 (2755 d 13:57 ago) Posting: # 17887 Views: 5,875 |
|
Hello, I have been following the tutorial in biostatistics by SA Julious (2004, DOI:10.1002/sim.1783). There, he mentions that it is possible to expect a priory a T/R ratio different to the unity (in a extent 0.8 to 1.20). However it is not clear to me, what criteria or in which cases can I assume an apriori ratio as big as 0.8 or 1.20, if knowingly I am trying to demonstrate bioequivalence and then I should be expecting a T/R ratio of 1.00. In a particular case I happen to have a test product with content of the active compound that is above 110% of the content of the reference product. Could this product be evaluated for bioequivalence, by designing a study with an apriori T/R ratio of 1.10? Edit: Category changed; I think this one fits better (was “Design Issues”). [Helmut] |
Helmut ★★★ ![]() ![]() Vienna, Austria, 2017-10-11 21:18 (2755 d 12:56 ago) @ CECIF Posting: # 17888 Views: 4,787 |
|
Hi CECIF, ❝ […] it is possible to expect a priory a T/R ratio different to the unity (in a extent 0.8 to 1.20). Sure. Note that in BE we are using a multiplicative model (or an additive on log-transformed data). Hence, a maximum accepted Δ of 20% translates into a BE-range of 0.80–1.25 in the raw domain (not 0.80–1.20). ❝ However it is not clear to me, what criteria or in which cases can I assume an apriori ratio as big as 0.8 or 1.20, if knowingly I am trying to demonstrate bioequivalence and then I should be expecting a T/R ratio of 1.00. If you would expect a T/R-ratio exactly at one of the BE-boundaries, power would equal the Type I Error – which is the nominal level of the test or lower. Anything else within the BE-range is fine, although T/R-ratios deviating a lot from unity could require extremely large sample sizes. ❝ In a particular case I happen to have a test product with content of the active compound that is above 110% of the content of the reference product. I would try to get a batch of the reference which is closer to the test. F.i., according to the EMA’s BE-GL contents should not differ more than 5%. Only if you could prove (!) that it was impossible to find a better matching batch, a content correction is acceptable if stated in the protocol. ❝ Could this product be evaluated for bioequivalence, by designing a study with an apriori T/R ratio of 1.10? In principle, yes. But think twice before going there. I suggest to get the package PowerTOST for the statistical system
Even if you will perform a content-correction don’t assume a T/R-ratio of 1.
— Dif-tor heh smusma 🖖🏼 Довге життя Україна! ![]() Helmut Schütz ![]() The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes |
CECIF ☆ Colombia, 2017-10-11 22:35 (2755 d 11:40 ago) @ Helmut Posting: # 17889 Views: 4,747 |
|
Thank you very much. Very clear and complete answer. |